Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)

PURPOSE: To assess the safety and pharmacokinetics and determine the recommended phase 2 dose (RP2D) of niraparib with apalutamide or abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: BEDIVERE was a multicenter, open-label, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Saad, Fred, Chi, Kim N., Shore, Neal D., Graff, Julie N., Posadas, Edwin M., Lattouf, Jean-Baptiste, Espina, Byron M., Zhu, Eugene, Yu, Alex, Hazra, Anasuya, De Meulder, Marc, Mamidi, Rao N. V. S., Bradic, Branislav, Francis, Peter, Hayreh, Vinny, Rezazadeh Kalebasty, Arash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149334/
https://www.ncbi.nlm.nih.gov/pubmed/33754187
http://dx.doi.org/10.1007/s00280-021-04249-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149334/
https://www.ncbi.nlm.nih.gov/pubmed/33754187
http://dx.doi.org/10.1007/s00280-021-04249-7

Ejemplares similares